[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556500":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":91,"collaborators":10,"id":94,"slug":10,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":10,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":10,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Untreated group",null,"The untreated patients who met the staging subgroups of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022 edition or lost HBsAg spontaneously.",{"label":13,"type":10,"description":14,"interventionNames":10},"NA treatment group","The patients who achieved HBV DNA suppression by NA.",[16],{"name":17,"affiliation":18,"role":19},"Qin Ning, Doctor","Department of infectious Diseases, Tongji Hospital","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","862783662391","qning@vip.sina.com",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Meifang Han, Doctor","mfan@foxmail.com",[29,46,57,69,80],{"facility":5,"status":30,"city":31,"state":32,"zip":10,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Wuhan","Hubei","China",{"type":35,"coordinates":36},"Point",[37,38],114.26667,30.58333,{"lat":38,"lon":37},[41,43],{"name":17,"role":22,"phone":42,"phoneExt":10,"email":24},"02783662391",{"name":44,"role":22,"phone":42,"phoneExt":10,"email":45},"Meifang Han","mfhan@foxmail.com",{"facility":47,"status":30,"city":48,"state":10,"zip":10,"country":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Beijing YouAn Hospital","Beijing",{"type":35,"coordinates":50},[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":56,"role":22,"phone":10,"phoneExt":10,"email":10},"Wei Hou",{"facility":58,"status":59,"city":60,"state":10,"zip":10,"country":33,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"The First Hospital of Jilin University","NOT_YET_RECRUITING","Changchun",{"type":35,"coordinates":62},[63,64],125.32278,43.88,{"lat":64,"lon":63},[67],{"name":68,"role":22,"phone":10,"phoneExt":10,"email":10},"Junqi Niu",{"facility":70,"status":59,"city":71,"state":10,"zip":10,"country":33,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Southwest Hospital","Chongqing",{"type":35,"coordinates":73},[74,75],106.55771,29.56026,{"lat":75,"lon":74},[78],{"name":79,"role":22,"phone":10,"phoneExt":10,"email":10},"Qing Mao",{"facility":81,"status":59,"city":82,"state":10,"zip":10,"country":33,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Jiangsu Province Hospital","Nanjing",{"type":35,"coordinates":84},[85,86],118.77778,32.06167,{"lat":86,"lon":85},[89],{"name":90,"role":22,"phone":10,"phoneExt":10,"email":10},"Chuanlong Zhu",{"type":19,"investigatorFullName":92,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Qin Ning","Director and Chair of Department of Infectious Diseases","100556500",false,"NCT06525909","A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B","Inclusion Criteria:\n\n1. Patients with CHB who were older than 18 years old and younger than 50 years old with HBsAg positivity more than 6 months;\n2. Group 1 untreated group fulfils any one of the four natural history types of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022.\n3. Group 2 nucleos(t)ide-treated CHB patients are required to have sustained control of their HBV DNA (\\\u003C100 IU\u002Fml).\n\nExclusion Criteria:\n\n1. Pregnancy status;\n2. Has been diagnosed with compensated\u002Flost compensated cirrhosis, hepatocellular carcinoma by imaging or other indicators;\n3. Combined HAV, HCV, HEV infection, schistosomal liver disease, drug-induced liver injury, autoimmune hepatitis, alcoholic liver disease, severe fatty liver, HIV infection;\n4. Being on immunosuppressants or immunomodulators or hormonal drugs or biological agents, etc;\n5. previous history of oncology, organ transplantation, etc., history of alcoholism (\\>30 g\u002Fd for men, \\>20 g\u002Fd for women);\n6. Inadequate follow-up time and inadequate clinical\u002Flaboratory information;\n7. Combined heart, brain, kidney, lung and other organ insufficiency or combined endocrine and haematological system and other major diseases;\n8. Comorbid serious psychiatric diseases including severe anxiety or depression;\n9. Unwilling to participate in this study.",true,"ALL","18 Years","50 Years",{"count":104,"type":105},250,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and grading criteria for the immune exhaustion status of patients with CHB.",[109],"Hepatitis B, Chronic","2024-07-24",{"date":112,"type":113},"2024-07-29","ACTUAL",{"date":115,"type":113},"2024-01-20",{"date":117,"type":105},"2028-12-10",{"name":5,"class":6},5]